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Infections with hepatitis C virus (HCV) genotype 3 exhibit differences in clinical phenotype including an increase in response to interferon
therapy and development of steatosis. To initiate studies on genotype 3, we created a chimeric genotype 1b replicon containing a genotype 3a
NS5A domain. The chimera was capable of efficient colony formation after the selection of a novel dominant adaptive mutation. Thus,
domains from highly different strains can interact to form a functional replicase. A new genotype 1a replicon was constructed as well.
Genotype specific influence on interferon sensitivity was examined using genotype 1a, 1b and chimeric 1b–3a replicons. The genotype 3a
NS5A domain did not increase the sensitivity of the chimeric replicon to IFNα. The results suggest that NS5A is not sufficient to convey the
increased IFNα response by genotype 3 or the replicon model is not capable of mimicking the events involved in increased sustained viral
response.
© 2006 Elsevier Inc. All rights reserved.Keywords: HCV; Interferon stimulated genes; ISG; IFNαIntroduction
Hepatitis C virus (HCV) infections are one of the leading
causes of liver disease worldwide with a prevalence of 2–3%.
Infections are typically asymptomatic for decades, yet 20% of
persistently infected individuals will eventually develop serious
liver disease including cirrhosis and liver cancer. HCV
infection is the leading cause for liver transplantation (Thomas
and Seeff, 2005; Alter and Seeff, 2005), and liver cancer due to
HCV infection is one of the most rapidly increasing types of
cancer in the U.S. (Kim et al., 2005; El Serag, 2004). The
current therapeutic treatment for HCV infection is pegylated
IFNα2 and ribavirin (reviewed in (Feld and Hoofnagle, 2005)
with rates of sustained viral clearance of 40–50% and 80–90%
for genotype 1 and genotype 2/3, respectively (Manns et al.,
2001; Fried et al., 2002).
Numerous studies have suggested that HCV evades the host
IFN response by several mechanisms (reviewed in Gale and⁎ Corresponding author. Fax: +1 210 670 3329.
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doi:10.1016/j.virol.2006.07.019Foy, 2005). Enomoto et al. first described a relationship between
resistance to IFNα therapy and sequence variation in a region of
NS5A designated the interferon sensitivity determining region
(ISDR) (Enomoto et al., 1996). Gale and colleagues demon-
strated that this region interacts with PKR, providing a plausible
mechanism for the modulation of the host response to IFN (Gale
et al., 1997, 1998). The use of microarray analyses has
supported the role of NS5A in blocking the IFN response
(Geiss et al., 2003; Girard et al., 2002), yet these studies, as well
as others, have suggested that PKR independent mechanisms
may also be involved in the NS5A suppression of the IFN
response (Podevin et al., 2001; Tan and Katze, 2001). Some
studies have suggested that NS5A induces IL8 synthesis that in
turn contributes to IFN resistance (Polyak et al., 2001; Girard et
al., 2002). NS5A has been shown to interact with a number of
proteins, including grb2, PI3 kinase (Tan et al., 1999) and hVAP
(Evans et al., 2004; Tu et al., 1999).
Recently, HCV NS3/4A protease has been shown to block
phosphorylation of IRF3 providing new insight into the
mechanisms by which HCV subverts the dsRNA-induced IFN
signaling pathways (Foy et al., 2003). NS3/4A blocks IRF3
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is the dsRNA binding helicase that activates the IRF3 and
NFκB pathways resulting in the induction of type 1 IFN
(Yoneyama et al., 2004). The HCV NS3/4a protease blocks
activation of IRF3 by this pathway (Foy et al., 2003, 2005)
via cleavage of a newly identified adapter protein (CARDIF,
IPS-1, MAVS, VISA) (Xu et al., 2005; Seth et al., 2005;
Kawai et al., 2005; Meylan et al., 2005). TLR3 activation of
IRF3 is suppressed by NS3/4A as well, via cleavage of its
essential adapter protein TRIF (Li et al., 2005; Foy et al.,
2003).
Although HCV does not replicate in conventional tissue
culture systems, a surrogate system has been created based on
a bicistronic replicon (Lohmann et al., 1999). The utility of
this system was enhanced by the recognition that adaptive
mutations arise that permit more efficient replication (Blight
et al., 2000) and by the isolation of highly permissive cell
lines derived by curing cells of the replicon (Blight et al.,
2003; Yi and Lemon, 2004). The identification of adaptive
mutations permitted the construction of replication competent
full-length genomes without foreign sequences (Ikeda et al.,
2002; Pietschmann et al., 2002). Recently, a true tissue
culture system was realized for HCV in which infection of
highly permissive cured Huh7 cell lines with a genotype 2
isolate results in efficient spread of the infection and secretion
of infectious virions (Lindenbach et al., 2005, 2006; Wakita et
al., 2005; Zhong et al., 2005). A genotype 1a clone capable
of producing infectious virus has been described recently as
well (Yi et al., 2006).
Infections with HCV genotype 3 are associated with an
increase in sustained response to IFNα therapy (Manns et
al., 2001; Fried et al., 2002) and an increase in risk for
steatosis (Gochee et al., 2003; Monto et al., 2002; Kumar et
al., 2002; Poynard et al., 2003). Currently, no genotype 3
replicon is available to address the mechanism for genotype
specific differences in clinical outcome. To evaluate the
role of NS5A in genotype specific differences in IFNα
sensitivity, we have constructed a chimeric replicon con-
taining the genotype 3a NS5A domain in a genotype 1b
background. Adaptive mutations in NS3 and NS5A were
required for replicon induced colony formation. The genotype
3a insert represents the simultaneous introduction of 92 amino
acid changes into the genotype 1b background, demonstrating
the remarkable capacity of the NS5A region for variation
without loss of function. The genotype 3a NS5A domain did not
increase the IFNα sensitivity of the 1b replicon, suggesting that
either NS5A is not sufficient for the clinical phenotype of
genotype 3 IFN sensitivity or that the current assays are not
capable of mimicking the genotype 3 phenotype observed in the
clinic.
Results
Selection of genotype 1b/3a chimeric replicons
To initiate studies on the genotype 3 specific clinical
phenotypes, we created a series of chimeric repliconsreplacing the NS3–NS5B, NS5A–NS5B, and NS5A regions
of a genotype 1b replicon (Rep1b) with genotype 3a
sequences. NS5A was selected as the primary target for the
initial studies, since it has been shown to correlate with
response to exogenous IFNα in the clinic, and thus may be
responsible for the genotype 3a phenotype. Although NS3/4A
interferes with the endogenous production of type 1 IFN, it is
not known to affect the response to exogenous IFNα.
Modified versions of each replicon were constructed to
contain the NS3-1431 mutation that enhances NS5A adaptive
mutations in both the genotype 1a (see below) and 1b
(Lanford et al., 2003) backgrounds. The only chimeric
replicon capable of inducing colony formation was the
replicon containing NS5A (hereafter designated Rep1b/3a).
The NS5A genotype 3a insert spanned amino acid residues
2056 to 2406 and was 26% divergent from the genotype 1b
sequence (92 of the 350 residues differed between genotype
3a and 1b; Fig. 1). Although transfection of parental Huh7
cells with Rep1b/3a without the NS3-1431 mutation failed to
produce colonies on multiple attempts, transfection of a cell
line cured of the genotype 1b replicon (Huh7-1bC) yielded
G418 resistant colonies at a low level. In contrast, Rep1b/3a
containing the NS3-1431 mutation was capable of low level
colony formation on parental Huh7 cells and formed
numerous colonies on the Huh7-1bC cell line (upper panel,
Table 1). Rep1b/3a with or without the 1431 mutation failed
to produce colonies in a Huh7 line cured of the genotype 1a
replicon (Huh7-1aC) that was highly efficient for colony
formation with a genotype 1a replicon (see below).
Cell lines were established from colonies derived by
transfection of Rep1b/3a with and without the NS3-1431
adaptive mutation. The NS3 and NS5A domains were
sequenced from seven cell lines (4 from Rep1b/3a and 3
from Rep1b/3a-1431). A dominant NS5A adaptive mutation
was identified in 6 of 7 replicons at amino acid residue 2195
(proline to serine or threonine) (Table 2). The one replicon
lacking a mutation at 2195 acquired a mutation at 2187
(alanine to glutamic acid) which has been identified as one of
the residues involved in hVAP interactions (Evans et al., 2004)
(see Discussion). The 2195 mutation has not been previously
identified in genotype 1b replicons, but 2195 is within the
domain of adaptive mutations identified in genotype 1b
replicons that are located immediately upstream of the PKR
binding and ISDR regions (Fig. 1B). NS3 mutations were
acquired by all replicons not already possessing NS3-1431.
Two of the replicons acquired NS3 mutations at 1109, which
represents the most amino terminal NS3 mutation identified in
any genotype 1b replicon to date. Thus, the inclusion of the
genotype 3 NS5A domain resulted in the selection of adaptive
mutations not previously recognized in genotype 1b replicons,
suggesting that insertion of a divergent NS5A sequence can
induce genotype specific compensatory mutations in distant
domains of the polyprotein.
To test the effect of the NS5A-2195 mutation on colony
formation, the P2195S mutation was introduced into Rep1b/3a
with or without the NS3-1431 mutation. Direct comparison of
the highly adapted Rep1b-1431/2204 (genotype 1b replicon
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Table 1





Rep1b/3a – – 10 μg 0 0 1
Rep1b/3a 1431 – 10 μg 3 0 112
Rep1b/3a – 2195 100 ng 5
Rep1b/3a 1431 2195 100 ng 864
Rep1b 1431 2204 100 ng 1312
Cell lines were transfected with replicon RNA at the indicated levels (RNA
Conc.) and colony formation was enumerated after selection with G418. The
adaptive mutations present in NS3 and NS5A for each replicon are indicated.
Huh7 cells were compared with cell lines cured of genotype 1a (Huh7-1aC) and
1b (Huh7-1bC) replicons. The upper and lower tables, divided by the horizontal
line, represent different experiments, after and before the chimeric replicon was
modified with the 2195 adaptive mutation.
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and Rep1b/3a-1431/2195 (chimeric replicon with NS5A-2195
and NS3-1431) indicated that the chimeric replicon approached
the same colony forming activity as the highly adapted Rep1b
replicon (lower panel, Table 1). Thus, with the appropriate
adaptive mutations, the highly divergent genotype 3a NS5A
region did not significantly decrease colony formation in a
genotype 1b background. These data demonstrate that regions
of the polyprotein from highly divergent genotypes are capable
of functional interaction for RNA replication.
Isolation of cell lines with genotype 1a replicon
To facilitate our studies on genotype specific IFN
sensitivity, we constructed a genotype 1a replicon based on
our infectious clone of the HCV-1 prototype strain (Lanford et
al., 2001). In our previous investigation, this genotype 1a
replicon failed to induce colony formation on parental Huh7
cells (Lanford et al., 2003) even after the addition of adaptive
mutations at NS3-1431 and NS5A-2204 (Rep1a-1431/2204).
However, following repeated large scale transfections, three
G418 resistant colonies were produced on parental Huh7
cells, one of which produced a stable cell line. The HCV-1
strain is closely related to H77, the other genotype 1a replicon
sequence, but differs by 78 amino acids of which 37 are in
the NS3–NS5B domain. In contrast, HCV-1 is 12.3%
divergent at the amino acid level from the genotype 1b
Con1 strain within NS3–NS5B region (245 of 1987 residues
differ; 49 in NS3 and 85 in NS5A; Fig. 1B). Sequencing of
the NS3–NS5B coding region of the genotype 1a replicon
revealed, in addition to the modifications at 1431 and 2204, a
single mutation at NS3-1202 changing a glutamic acid toFig. 1. Schematic of the HCV replicon. (A) The bicistronic subgenomic HCV repli
neomycin phosphotransferase gene and the nonstructural proteins of HCV, respectiv
Honda et al. (1999). The nonstructural region of the polyprotein is depicted as a recta
NS5A protein is expanded to illustrate the region within NS5A of the Rep1b replaced
region is aligned for the comparison of the genotype 1a, 1b and 3a sequences. The a
containing clustered adaptive mutations is underlined (residues 2163–2205), as is th
adaptive mutation arising in the Rep1b/3a replicon is indicated by an asterisk.lysine. To test the contribution of the 1202 mutation to colony
formation, it was inserted into Rep1a with and without the
1431 and 2204 mutations. Transfection of genotype 1a
replicons with the different mutation combinations revealed
that all three mutations were required for colony formation on
parental Huh7 cells, but that either single NS3 mutation in
combination with NS5A-2204 was sufficient to yield a low
level of colonies on the cured cell lines Huh7-1aC and Huh7-
1bC (Table 3). Since the Huh7-1aC line was derived from the
original single genotype 1a colony from parental Huh7 cells,
it was possible that this line represented the selection of cell
type more permissive for the genotype 1a replicon; however,
side by side comparisons revealed that the Huh7-1bC cell line
was the most permissive for all Rep1a replicons, especially
those with a single NS3 mutation (Table 3). Comparison of
the Rep1a-1202/1431/2204 and Rep1b-1431/2204 replicons
for colony formation following transfection at several RNA
concentrations revealed that, although the Rep1a with 3
adaptive mutations was highly efficient at colony formation, it
was less efficient than the highly adapted Rep1b-1431/2204
replicon (lower portion Table 3).
Steady state copy number for genotype 1a, 1b and chimeric
1b/3a replicons
The various replicon cell lines isolated during the course of
these studies were compared for steady state copy number of the
replicon. Cells were harvested under subconfluent growth
conditions, and copy number was expressed as genome
equivalents (GE) per μg of cell RNA (Fig. 2). On a per cell
basis, steady state copy number ranged from 30 to 1300 GE per
cell. All seven Rep1b/3a cell lines had lower copy number than
either the Rep1b or Rep1a cell lines. On average, the Rep1b/3a
lines had 4.5-fold lower copy number (Fig. 2). All the cell lines
being compared were derived from the clonal Huh7-1bC cell
line, so the cellular backgrounds were near identical in this
comparison. The reduction in copy number in the Rep1b/3a
lines appears to be characteristic of the chimeric replicon and
may reflect a partial incompatibility of the genotype 3a NS5A
sequence with the genotype 1b replicase that was not
overcome by adaptive-compensatory mutations. However,
since the entire genotype 3a NS5A sequence is not present
in Rep1b/3a, the lower replication may be due to the
chimerism of NS5A itself.
Genotype related sensitivity of replicons to IFNα
To examine the IFNα sensitivity of the chimeric genotype
1b/3a replicons in comparison to genotype 1a and 1b replicons,con is illustrated. The HCV IRES and EMCV IRES regulate translation of the
ely. The depiction of the HCV IRES was adapted from the structural studies of
ngle with demarcation of the individual viral protein domains. A domain of the
with a genotype 3 sequence to create Rep1b/3a. (B) The sequence of the NS5A
mino acid numbering at the left is with respect to the HCV genome. The region
e region containing the ISDR (2209–2248). The position of the dominant 2195
Fig. 2. Steady state copy number of the replicon RNA in cell lines. Cell lines
containing various replicons were harvested under subconfluent growth
conditions, and replicon RNA copy number was determined by TaqMan RT-
PCR and expressed as genome equivalents (GE) per μg of cell RNA. All seven
Rep1b/3a cell lines had lower copy number than either the Rep1b or Rep1a cell
lines. All the cell lines being compared were derived from the clonal Huh7-1bC
cell line, cured of the Rep1b replicon, so the cellular backgrounds were near
identical in this comparison.
Table 2
Adaptive mutations in 1b/3a replicons
Replicon NS3 NS5A
Rep1b/3a Clone 22-1 1279 Thr→Lys 2195 Pro→Ser
2203 Ala→Val
Rep1b/3a Clone 22-2 1109 Val→Asp 2195 Pro→Ser
1202 Glu→Gly
Rep1b/3a Clone 121-1 1226 Ala→Gly 2195 Pro→Thr
1587 Val→ Ile
Rep1b/3a Clone 121-3 1279 Thr→Lys 2195 Pro→Thr
Rep1b/3a-1431 Clone 122-1 1431 Asp→Tyr 2195 Pro→Ser
Rep1b/3a-1431 Clone 122-4 1431 Asp→Tyr 2195 Pro→Thr
Rep1b/3a-1431 Clone 122-5 1109 Val→Asp 2187 Ala→Glu
1431 Asp→Tyr
Replicons resident in cell lines established with Rep1b/3a were sequenced as
described in the text. Adaptive mutations in the NS3 and NS5A domains are
indicated by amino acid number and amino acid change.
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level IFNα; (2) replicon response to low level IFNα; and (3)
host response to IFNα. In the first experiment, cell lines
were treated with 1000 U/ml IFNα2b for 1, 2 or 3 days, and
the replicon levels were determined by TaqMan RT-PCR.
The level of replicon RNA declined by 4- to 10-fold by day
1, and 80- to 285-fold by day 3 (Fig. 3). The two Rep1b/3a
cell lines did not exhibit a greater decline in replicon RNA
levels than the Rep1a and Rep1b cell lines. The Rep1b and
Rep1b/3a lines exhibited very similar responses to IFNα.
Again, it should be noted that all of the replicon lines had
the same cellular background, being derived from the clonal
Huh7-1bC cell line. The greatest decline in replicon RNA
was observed in the Rep1a Clone 4 line, which exhibited a
2-fold greater decrease in comparison to the other cell lines
at all time points. Comparison of Rep1a Clone 4 to the other
Rep1a cell lines suggested that this increased IFNα
sensitivity was primarily due to clonal differences ratherTable 3




NS3 NS5A Huh7 Huh7-1aC Huh7-1bC
Rep1a – – – 10 μg 0 0 0
1202 – – 10 μg 0 0 0
1202 – 2204 10 μg 0 5 135
– 1431 2204 10 μg 0 1 72
1202 1431 2204 10 μg 704 ∼2000 ∼3000
Rep1b – 1431 2204 0.01 μg 74 0 1056
– 1431 2204 10 μg nd 100 nd
Rep1a 1202 1431 2204 0.4 μg nd 0 414
Rep1b – 1431 2204 0.2 μg nd 0 624
Cell lines were transfected with replicon RNA at the indicated levels (RNA
Conc.) and colony formation was enumerated after selection with G418. The
adaptive mutations present in NS3 and NS5A for each replicon are indicated.
Huh7 cells were compared with cell lines cured of genotype 1a and 1b replicons.
The upper and lower tables, divided by the horizontal line, represent different
experiments. –, no mutation; nd, not done; TMTC, too many to count.than a genotype difference (compare Rep1a-4 vs. Rep1a-8
and Rep1b-35, Fig. 4).
In the second set of experiments, we examined whether the
Rep1b/3a replicons might be sensitive to lower levels of IFNα
than the other replicons. Two cells lines for each replicon were
treated in duplicate for 72 h with different levels of IFNα (0, 5,
25 and 100 U/ml). The Rep1b and Rep1b/3a lines were very
similar and had IC50s of approximately 5 U/ml, while the Rep1aFig. 3. Effect of replicon genotype on inhibition with IFNα treatment. Replicon
cell lines derived with the Rep1a (clone 4), Rep1b (clone 35) and chimeric
Rep1b/3a (clones 22-2 and 122-5) were treated with 1000 U/ml of IFNα for
3 days. Adaptive mutations present in the Rep1b/3a replicons are described in
Table 2. Fresh medium and IFNα were provided on day 2. Replicon RNA
levels were determined each day by quantitative RT-PCR and compared to
untreated cells harvested at the same time to determine the fold decrease in
RNA levels. RNA levels were first normalized as genome equivalents (GE) per
μg of cell RNA. All cell lines were derived from the same clonal line (Huh7-
1bC, cured of the Rep1b replicon) in order to have near identical cell
backgrounds.
Fig. 4. Effect of genotype on IFNα IC50. Duplicate cultures of cell lines derived
with the Rep1a (clones 4 and 8), Rep1b (clones 7 and 35) and chimeric Rep1b/
3a (clones 121-3 and 122-5) were treated with different levels of IFNα for
3 days. Adaptive mutations present in the Rep1b/3a replicons are described in
Table 2. Fresh medium and IFNα were provided on day 2. Replicon RNA levels
were determined each day by quantitative RT-PCR and compared to untreated
cultures of each cell line harvested at the same time to determine the fold
decrease in RNA levels. RNA levels were first normalized as genome
equivalents (GE) per μg of cell RNA. With the exception of 1b-7, all cell
lines were derived from the same clonal line (Huh7-1bC; cured of the Rep1b
replicon) in order to have near identical cell backgrounds. The IFNα IC50 was
approximately 5 U/ml for the 1b and 1b/3a cell lines and was less than 1 U/ml for
the 1a cell lines.
Table 4
Interferon induced increase in ISG transcripts in replicon cell lines
RNA Time Huh7 Huh7-1bC Rep1b Rep1a Rep1b/3a
HCV 4 h 1 1 1
8 h 1 1 1
24 h −4 −5 −4
48 h −36 −48 −21
72 h −143 −121 −95
IFIT2 4 h 691 603 534 317 578
8 h 369 440 940 186 480
24 h 7 9 52 22 104
48 h 6 5 10 6 14
72 h 6 7 13 11 2
CXCL11 4 h 11 21 8 50 12
8 h 35 80 21 104 25
24 h 3 3 20 23 9
48 h 4 3 7 3 3
72 h 3 Nd nd 3 3
CXCL10 4 h 8 4 4 24 7
8 h 23 18 47 14 13
24 h 3 2 13 16 7
48 h 6 3 1 3 3
72 h 2 2 2 3 2
MX 1 4 h 112 338 241 96 106
8 h 700 1828 2333 944 357
24 h 500 800 919 371 409
48 h 222 828 696 238 656
72 h 126 559 415 131 465
OAS3 4 h 8 36 44 28 29
8 h 29 155 200 93 236
24 h 14 71 73 36 138
48 h 15 75 79 28 106
72 h 22 63 50 22 93
ISG12 4 h 14 12 16 12 9
8 h 113 228 144 131 100
24 h 114 231 141 143 152
48 h 147 158 147 66 177
72 h 223 270 175 91 219
Cell lines were treated with 1000 U/ml of IFNα for 72 h. Fresh media and IFNα
were provided every 24 h. The levels of replicon RNA and ISG transcripts were
determined by quantitative RT-PCR and expressed as fold change in comparison
to untreated cultures harvested at each time point.
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lines exhibited marginally greater sensitivity to IFNα, and
Rep1a Clone 4 was the most sensitive (Fig. 4). These data
indicate that the genotype 3 NS5A region did not increase the
IFNα sensitivity of the Rep1b replicon.
Finally, we examined the ability of the replicons to alter the
downregulation of the ISG response. Our recent studies on
host gene expression in uninfected chimpanzees following a
single dose of IFNα revealed that the ISG response was
rapidly downregulated in vivo in both the liver and PBMC.
Most genes reached peak response within 4 h and had
returned to baseline values by 24 h, even in the continuing
presence of high levels of circulating pegylated IFNα
(Lanford et al., 2006). Thus, the increased response of
genotype 3a to IFNα therapy could potentially be related to a
disruption in the ability of the cell to downregulate the ISG
response. We selected six genes from the in vivo microarray
data from chimpanzees to examine for the influence of the
chimeric replicon on downregulation of the ISG response. We
selected three genes that were rapidly downregulated in vivo
and three genes that were not rapidly downregulated. The
genes that were not rapidly downregulated by 24 h in vivo
represented a small minority of the total ISGs (Lanford et al.,
2006). The three representative genes that were rapidly
downregulated in vivo included IFIT2 (alias ISG54),
CXCL11 (alias I-TAC) and CXCL10 (alias IP-10). I-TAC
and IP-10 represent CXCR3 chemokines that are expressed by
hepatocytes (Bigger et al., 2004; Helbig et al., 2004; Lanford
et al., 2006) and are involved in recruitment of lymphocytes to
sites of inflammation. The three representative genes that werenot downregulated in vivo included MX1, OAS3 and ISG12.
MX1 and OAS are known to have antiviral activity in a
number of model systems.
Huh7 cells, Huh7-1bC and three replicon lines (one each
for genotypes 1a, 1b and 1b/3a) were treated with IFNα at
1000 U/ml for 72 h with changes of medium and IFNα every
24 h. Analysis of replicon levels revealed a pattern similar to
those described above. A 24 h lag in the decline of replicon
levels was followed by a decline of 95- to 143-fold over 72 h,
with the chimeric replicon being no more sensitive to IFNα
than the other genotypes (Table 4). The ISG transcripts were
upregulated from 20-fold to greater than 2000-fold following
IFNα treatment (Table 4). Transcript levels were measured by
TaqMan RT-PCR at 4, 8, 24, 48 and 72 h. The representative
genes that were rapidly downregulated in vivo were also
rapidly downregulated in Huh7 cells, the cured cell line and
all three of the replicon lines (Fig. 5). The genes not
downregulated in vivo were also not downregulated in Huh7
cells or the replicon lines. None of the replicons appeared to
Fig. 5. Effect of replicon genotype on ISG induction upon IFNα treatment. Cell lines derived with Rep1a (clone 8), Rep1b (clone 35) and chimeric Rep1b/3a (clone
122-5) and the Huh7-1bC cured line were treated with IFNα for 72 h with fresh medium and IFNα being provided every 24 h. Treated and untreated cultures were
harvested at 4, 8, 24, 48 and 72 h. Total cell RNAwas analyzed by quantitative RT-PCR to determine the levels of transcripts for the interferon stimulated genes IFIT2
(ISG54), CXCL11 (I-TAC), CXCL10 (IP-10), MX1, OAS3 and IFI27 (ISG12). Fold increase was determined by normalization to transcript copy per μg of cell RNA
and comparison to untreated cultures of each cell line harvested at the same times (see Table 4 for fold increase values). Percent increase was determined for each
transcript by normalization to the highest value during the time course.
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regulation in comparison to the Huh7-1bC cell line used for
their derivation (Table 4; Fig. 5). Thus, the NS5A genotype 3a
insert did not alter the host response to IFNα or the ability of the
cell to downregulate the ISG response.Discussion
The development of a replicon system for HCV has provided
a means to conduct numerous studies not previously possible,
including the evaluation of antiviral compounds. Studies with
199R.E. Lanford et al. / Virology 355 (2006) 192–202the replicon have demonstrated the direct antiviral activity of
IFNα and IFNγ (Lanford et al., 2003; Frese et al., 2002; Blight
et al., 2000; Guo et al., 2001; Frese et al., 2001; Cheney et al.,
2002). In the current study, we developed a chimeric 1b/3a
replicon containing the genotype 3a NS5A region and a new
genotype 1a replicon based on the HCV-1 genotype 1a
sequence. An important aspect of these studies was the
development of cell lines cured of the replicon by antiviral
treatment. Genotype 1a replicons were originally described by
Blight et al. (2003). Similar to our original findings (Lanford et
al., 2003), these investigators failed to obtain colony formation
in Huh7 cells even with a 1a replicon containing the NS5A-
2204 adaptive mutation. However, a low level of colony
formation was attained by using a highly permissive Huh7
variant derived by curing a replicon line with IFNα (Blight et
al., 2002). The established 1a replicons had acquired mutations
in NS3 at 1226 and 1496. Gu et al. also selected a cell line with a
1a replicon based on the H77 sequence containing the 2204
mutation. The replicon had acquired mutations in NS3 at
residues 1358 and 1609 (Gu et al., 2003). Yi et al. described a
highly efficient H77 genotype 1a replicon derived by
progressively replacing domains of the genotype 1b sequence
with genotype 1a with sequential addition of selected adaptive
mutations into the genotype 1a replicon (Yi and Lemon, 2004).
Reconstruction of a full-length clone with this adapted H77
sequence provided high level replication and production of
infectious particles in Huh7.5 cells (Yi et al., 2006).
The 1a replicon in the current study was based on an
infectious clone (Lanford et al., 2001) of the prototype HCV-1
sequence and is the only non-H77 genotype 1a replicon
described. The HCV-1 sequence was not capable of significant
colony formation on Huh7 cells, despite adaptive mutations at
both NS3-1431 and NS5A-2204. The acquisition of a second
NS3 mutation at 1202 dramatically altered the host range and
colony forming activity of this replicon. The 1a with two NS3
mutations was comparable in colony forming activity to the
adapted 1b replicon on cells cured of the genotype 1b replicon
(Huh7-1bC) and exceeded the 1b replicon on cells cured of the
1a replicon (Huh7-1aC).
The significance of NS3 mutations has not been elucidated,
but in our studies, their primary effect appears to be the
enhancement of NS5A mutations since by themselves NS3
mutations do not appear to enhance replicon activity (Lanford et
al., 2003). Almost all of the NS3 adaptive mutations described
to date in both genotype 1a and 1b replicons lie within residues
1202 to 1609 of the helicase domain. Interestingly, the 1b/3a
replicons extended the border for genotype 1b NS3 mutations to
include a mutation at 1109, well within the protease domain.
Two independent lines contained this mutation, each of which
had a second distinct NS3 mutation (1202 or 1431). The only
other report of an adaptive mutation in the protease domain was
an NS3 mutation at residue 1067 in a genotype 1a replicon (Yi
and Lemon, 2004).
The isolation of replicons based on divergent genotypes has
provided a means to explore the nature of genotype specific
differences in IFNα sensitivity. We engineered replicons based
on the 1b sequence with a genotype 3a NS5A domain sincemultiple studies have implicated NS5A in evasion of host IFN
response. It was surprising that a chimeric containing an NS5A
sequence with 26% divergence from the 1b NS5A (equivalent
to 92 simultaneous amino acid substitutions) would be
replication competent. NS5A has been shown to be highly
tolerant of mutations in the replicon model. The initial studies
on adaptive mutations revealed a deletion of 47 amino acids
downstream of the hyperphosphorylation domain that enhanced
replication (Blight et al., 2000). Another deletion was identified
in a replicon recovered from HeLa cells (Zhu et al., 2003).
Additional studies have revealed that the carboxyl terminus of
NS5Awill accept large insertions including GFP (Fiedler et al.,
2004; Moradpour et al., 2004). Yet, random insertions
throughout the NS5A domain were lethal except for two
positions in the C-terminus of the protein (Moradpour et al.,
2004). Collectively, these studies indicate that the replicon
system is tolerant of changes in specific regions of NS5A and at
the same time is highly dependent on specific adaptive
mutations in NS5A.
NS5A is a zinc-binding protein of unknown function
(Tellinghuisen et al., 2004) that exists as two phosphorylated
forms: basal phosphorylated p56 and hyperphosphorylated p58.
Adaptive mutations within and outside of NS5A tend to
decrease hyperphosphorylation (Evans et al., 2004; Appel et al.,
2005; Blight et al., 2000), and thus an association exists
between decreased phosphorylation and RNA replication. This
concept is further supported by the effect of kinase inhibitors
that decrease NS5A p58 and increase HCV RNA replication
(Neddermann et al., 2004). The association extends further to
include the interaction with hVAP. Mutations affecting
hyperphosphorylation increase the interaction between hVAP
and NS5A, including adaptive mutations in NS4B (Evans et al.,
2004). Interestingly, the dominant adaptive mutation in the
genotype 1b/3a replicon was a proline to serine/threonine
mutation and thus differs from most adaptive mutations in being
the addition of a potential phosphorylation site rather than the
loss of a serine or threonine. Nonetheless, presumably the 2195
mutation functions for genotype 3 NS5A in a manner similar to
the 2204 mutation for genotypes 1a and 1b. The one clone that
did not contain the adaptive mutation at 2195 contained a
mutation at 2187, one of the residues involved in hVAP
interaction.
The ISDR of NS5A (Enomoto et al., 1996) has been
recognized in multiple clinical studies, and in vitro studies of
variant NS5A proteins have supported the importance of this
region in IFNα response. Different studies have supported both
PKR-dependent (Gale et al., 1997, 1998) and PKR-independent
modulation of the IFNα response by NS5A (Geiss et al., 2003;
Girard et al., 2002; Podevin et al., 2001; Tan and Katze, 2001).
Amino acid variations in genotype 3 strains that were associated
with IFNα resistance were independent of the PKR pathway
(Castelain et al., 2002). Our studies did not observe an increased
sensitivity to IFNα for 1b replicons containing a genotype 3a
NS5A. One possible interpretation of these results is that the
NS5A region is not sufficient to convey the genotype 3
phenotype for increased IFNα sensitivity. Recent studies have
demonstrated that NS3/4a blocks the dsRNA-induced activation
200 R.E. Lanford et al. / Virology 355 (2006) 192–202of IRF3 (Foy et al., 2003; Li et al., 2005; Foy et al., 2005), a
critical component of the type 1 IFN response pathway.
Although NS3/4a is involved in blocking endogenous type 1
IFN production, no data suggest that it is involved in resistance
to exogenous sources of IFN. Other viral proteins may be
involved in HCV resistance to IFN, as well. However, it is not
clear that the replicon system is the appropriate model to test for
this phenotype. Increased sustained viral clearance is a complex
end point that is not completely understood and may not
necessarily translate to an observable in vitro phenotype. Full-
length genotype 3 replicons without foreign sequences may be
required to determine whether the genotype 3 phenotype of
increased sustained viral response in patients can be observed as
an in vitro phenotype.
Materials and methods
Replicon constructs
Rep1b was previously described (Lanford et al., 2003) and
was constructed to be an exact copy of the replicon described
by Lohmann et al. (1999) (GenBank accession no. AJ242652).
A highly adapted version of this genotype 1b replicon
containing the NS3-1431 and NS5A-2204 mutations (Rep1b-
1431/2204) was isolated and characterized in our previous
studies (Lanford et al., 2003). The chimeric Rep1b/3a
replicons were constructed by inserting the NS5A coding
region from a genotype 3a strain into the Rep1b backbone
(Figs. 1A and B). The HCV genotype 3a strain was recovered
from a chronically infected chimpanzee that was originally
inoculated with a NonA, NonB hepatitis contaminated blood
product. The NS5A region was amplified from serum derived
RNA using primers that spanned nucleotide numbers 5041 to
6041 (GenBank; AY587021), and thus the amino and carboxy
termini of NS5A (93 and 19 amino acids, respectively) are still
genotype 1b in the chimeric replicon. The forward and reverse
primers included restriction sites for Mlu1 and BamH1,
respectively, which are unique in the Rep1b construct and
allowed for the insertion of the genotype 3a sequences in-
frame with the Rep1b sequences. The Rep1b/3a replicons were
further modified by introduction of the NS3-1431 mutation
that is highly synergistic with NS5A adaptive mutations
(Lanford et al., 2003) and NS5A-2195 that was a dominant
mutation selected after transfection of Rep1b/3a. The Rep1a
construct has been previously described (Lanford et al., 2003)
and is identical to the Rep1b construct except that all HCV
components were derived from the HCV-1 genotype 1a
infectious clone (Lanford et al., 2001) (GenBank accession
no. AF271632) including the 5′ NCR, the NS3–NS5B
encoding region and the 3′ NCR. The Rep1a variant used in
this study contained 228 nucleotides (1927 to 2155) derived
from Rep1b, which altered 12 of the first 73 amino acids of
NS3 (Lanford et al., 2003). Subsequent replacement of this
region with the 1a sequence did not noticeably affect the
activity of the replicon.
Adaptive mutations in the Rep1a cell lines were identified by
direct sequencing of PCR products that spanned the entire NS3-5 open reading frame, while adaptive mutations in the Rep1b/3a
cell lines were detected by direct sequencing of PCR products
that spanned the entire NS3 domain (3420–5474) and most of
the NS5A domain (6527–7474). Specific adaptive mutations
were introduced into replicons using PCR directed mutagenesis.
Synthetic replicon RNA was prepared from Sca1 (Rep1b and
Reb1b/3a) and Xba1 (Rep1a) linearized DNA using the T7
Megascript Kit (Ambion, Austin, TX) and was purified by
DNase treatment, RNazol (Leedo; Houston, TX) extraction and
ethanol precipitation. RNA was quantified by optical density,
and concentrations and quality were confirmed by agarose gel
electrophoresis.
Cells and transfections
Huh7 cells were cultivated in a 1:1 mixture of Dulbecco's
modified Eagles medium and Ham's F12 medium (DMEM-
F12) supplemented with 10% fetal bovine serum (FBS) and
50 μg/ml of gentamicin sulfate. RNA transfections were
performed using DMRIE-C (Carlsbad, CA). Replicons with
low or no colony forming efficiency were transfected using
10 μg of replicon RNA per 100 mm culture dish; however,
replicons with adaptive mutations were transfected at 1 to
0.01 μg of replicon RNA adjusted to 10 μg with Huh7
RNA. Culture medium was supplemented with 250 μg/ml of
G418 beginning 1 day after transfection. This transfection
protocol routinely yielded 25–50% transfection efficiency for
RNA as evaluated by transfection of a Sindbis replicon
expressing β-galactosidase. Cell lines highly permissive in
replicon colony formation assays were derived by using
IFNα to cure cells of the genotype 1b (Huh7-1bC) or
genotype 1a (Huh7-1aC) replicons, as previously described
(Blight et al., 2002).
TaqMan quantitative RT-PCR for replicon RNA and
host transcripts
Total cell RNAwas isolated from cell cultures using RNazol
(Leedo, Houston, TX). Replicon RNAwas quantified by a real
time, 5′ exonuclease RT-PCR (TaqMan) assay exactly as
previously described (Lanford et al., 2001, 2003). The
conditions for quantification of transcripts from IFN-stimulated
genes (ISGs) were identical to those described for replicon
RNA. Assays for host transcripts were purchased from ABI as
Assays on Demand (Foster City, CA).
Antiviral treatments
IFNα2b (Intron A) was a gift from Schering Plough
Research Institute (Kenilworth, NJ). Antiviral studies were
initiated 24 h post-plating when cultures were still subconfluent.
None of the antiviral treatments induced noticeable toxicity by
microscopic inspection of the cultures.
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